Drug Profile
Safinamide - Newron Pharmaceuticals
Alternative Names: EMD 1195686; Equfina; FCE 26743; ME 2125; NW 1015; Onstryv; PNU 151774; PNU 151774E; Safinamide mesilate; Safinamide mesylate; Xadago; ZP-034Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Eisai Co Ltd; Meiji Seika Pharma; Merck Serono; Newron Pharmaceuticals; US WorldMeds; Valeo Pharma; Zambon SpA
- Class Amides; Antidementias; Antiepileptic drugs; Antiparkinsonians; Benzylamines; Fluorobenzenes; Neuroprotectants; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease
- Phase II Drug-induced dyskinesia; Multiple system atrophy
- Discontinued Alzheimer's disease; Epilepsy; Restless legs syndrome
Most Recent Events
- 14 Mar 2023 Newron and Zambon have reached an agreement to discontinue their plans to initiate a clinical study with safinamide in Parkinson’s disease
- 07 Oct 2021 Zambon completed the phase III trial in Parkinson's disease (Treatment-experienced, Adjunctive treatment) in China (PO) (NCT03881371)
- 16 Sep 2021 Newron Pharmaceuticals and Zambon plan a study to demonstrate the anti-dyskinetic effect of safinamide in Parkinson’s disease patients with Levodopa Induced Dyskinesia in USA, Europe, Asia, Australia in the fourth quarter of 2022